Polyethylene glycol loxenatide

Active substance
Polyethylene glycol loxenatide
Domain
Metabolism and Endocrinology
Reason of inclusion in Horizonscan Geneesmiddelen
New medicine (specialité)
Main indication
Diabetes
Extended indication
In combination with metformin in patients with type 2 diabetes mellitus.

1. Product

Manufacturer
Jiangsu Hengrui
Mechanism of action
GLP-1 receptor agonist
Route of administration
Subcutaneous
Therapeutical formulation
Injection
Budgetting framework
Extramural (GVS)
Additional comments
GLP-1 Receptor Agonist Bekostiging mogelijk extramuraal conform andere glp-1 agonisten

2. Registration

Registration route
Centralised (EMA)
Submission date
2020
Expected Registration
2021
Orphan drug
No
Registration phase
Clinical trials
Additional comments
Verwachte indiening gebaseerd op actual primary completion date fase 3 studie in datum in 2016.

3. Therapeutic value

Current treatment options
Andere GLP1-agonisten.
Therapeutic value
No judgement
Frequency of administration
1 times a week
Dosage per administration
100µg
References
NCT02477969

4. Expected patient volume per year

References
GIPdatabank
Additional comments
Totale GLP-1 klasse in 2017 volgens GIP 12.919 gebruikers.

5. Expected cost per patient per year

There is currently nothing known about the expected cost.

6. Potential total cost per year

There is currently nothing known about the possible total cost.

7. Off label use

There is currently nothing known about off label use.

8. Indication extension

There is currently nothing known about indication extensions.

9. Other information

There is currently no futher information available.